


NASH DRUG DEVELOPMENT

A COMPETITIVE EDGE FOR SPONSORS

INTEGRATED NASH EXPERTISE



IMAGING CORE LABORATORY

MR- AND ULTRASOUND-BASED BIOMARKERS FOR NASH STUDIES

- QUANTITATIVE VOLUMETRIC IMAGING (MRI)
- PROTON DENSITY FAT FRACTION (MRI-PDFF)
- ELASTOGRAPHY (MRE)
- SPECTROSCOPY (MRS)
- VIBRATION CONTROLLED TRANSIENT ELASTOGRAPHY +/- CONTROLLED ATTENUATION PARAMETER (VCTE+/-CAP)

STRATEGIC EXECUTION

EXPERT MANAGEMENT

- EXPERIENCED OPERATIONAL TEAMS
- IN-HOUSE PHYSICIANS
- GLOBAL REGULATORY

GLOBAL EXPERIENCE

NASH TRIAL MANAGEMENT SINCE 2010

15
COUNTRIES

2500+
SUBJECTS

200+
SITES

CENTRAL LAB CAPABILITIES

NASH BIOMARKER STRATEGIC SERVICES

- CYTOKERATIN – 18 (M30 AND M65)
- APOLIPOPROTEIN A1
- APOLIPOPROTEIN B
- LEPTIN
- ADINOPONECTIN
- RESISTIN
- FREE FATTY ACIDS
- GHRELIN
- hsCRP
- INTERLEUKIN-6
- TNF α
- ELF: TIMP-1, HA, P3NP
- PATHOLOGY/LIVER BIOPSY